89 related articles for article (PubMed ID: 7166220)
1. Pregnancy categories for prescription drugs.
FDA Drug Bull; 1982 Dec; 12(3):24-5. PubMed ID: 7166220
[No Abstract] [Full Text] [Related]
2. Drug labeling for teratogenicity: requirements of the U.S. Food and Drug Administration.
Kelsey FO
Prog Clin Biol Res; 1985; 163C():155-9. PubMed ID: 3991617
[No Abstract] [Full Text] [Related]
3. Teratology public affairs committee position paper: Pregnancy labeling for prescription drugs: Ten years later.
Public Affairs Committee of the Teratology Society
Birth Defects Res A Clin Mol Teratol; 2007 Sep; 79(9):627-30. PubMed ID: 17663419
[No Abstract] [Full Text] [Related]
4. Content and format of labeling for human prescription drugs; pregnancy labeling; public hearing--FDA. Notice of public hearing; request for comments.
Fed Regist; 1997 Jul; 62(147):41061-3. PubMed ID: 10169832
[TBL] [Abstract][Full Text] [Related]
5. Pregnancy labeling.
FDA Drug Bull; 1979 Sep; 9(4):23-4. PubMed ID: 488582
[No Abstract] [Full Text] [Related]
6. Methods of evaluating the alleged teratogenicity of environmental agents.
Brent RL
Prog Clin Biol Res; 1985; 163C():191-5. PubMed ID: 3991621
[No Abstract] [Full Text] [Related]
7. Trends in adherence to a revised risk management program designed to decrease or eliminate isotretinoin-exposed pregnancies: evaluation of the accutane SMART program.
Brinker A; Kornegay C; Nourjah P
Arch Dermatol; 2005 May; 141(5):563-9. PubMed ID: 15897377
[TBL] [Abstract][Full Text] [Related]
8. Potential subversion of pregnancy prevention program in the managed care setting.
Wilkin JK
Arch Dermatol; 1997 Feb; 133(2):243-4. PubMed ID: 9041846
[No Abstract] [Full Text] [Related]
9. FDA classification of drugs for teratogenic risk. Teratology Society Public Affairs Committee.
Teratology; 1994 Jun; 49(6):446-7. PubMed ID: 7747265
[TBL] [Abstract][Full Text] [Related]
10. Drug safety labeling for doctors.
Hecht A
FDA Consum; 1979 Oct; 13(8):12-3. PubMed ID: 10309108
[TBL] [Abstract][Full Text] [Related]
11. The importance of epidemiology in identifying drugs which may cause malformations--with particular reference to drugs containing sex hormones.
Kelsey FO
Acta Morphol Acad Sci Hung; 1980; 28(1-2):189-95. PubMed ID: 7004099
[No Abstract] [Full Text] [Related]
12. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
Kweder SL
Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
[No Abstract] [Full Text] [Related]
13. Content and format for labeling for human prescription drugs; amendment of effective date for certain biological products--Food and Drug Administration. Final rule.
Fed Regist; 1981 Jan; 46(15 pt 1):7271-3. PubMed ID: 10249526
[TBL] [Abstract][Full Text] [Related]
14. What is prescription labeling communicating to doctors about hepatotoxic drugs? A study of FDA approved product labeling.
Willy ME; Li Z
Pharmacoepidemiol Drug Saf; 2004 Apr; 13(4):201-6. PubMed ID: 15255086
[TBL] [Abstract][Full Text] [Related]
15. Progestational drug products for human use; requirements for labeling directed to the patient. Food and Drug Administration, HHS. Final rule.
Fed Regist; 1999 Nov; 64(220):62110-2. PubMed ID: 11010691
[TBL] [Abstract][Full Text] [Related]
16. Revised physician labelling for neuroleptic drugs: Food and Drug Administration. Notice.
Fed Regist; 1980 Aug; 45(155):52931-3. PubMed ID: 10314517
[TBL] [Abstract][Full Text] [Related]
17. Food and Drug Administration--Prescription drug products; patient package inserts requirements. Final rule.
Fed Regist; 1980 Sep; 45(179 Pt 2):60754-84. PubMed ID: 10248285
[TBL] [Abstract][Full Text] [Related]
18. Isotretinoin prescribing: finding a balance between benefit and risk.
Stern RS
Pharmacoepidemiol Drug Saf; 2005 Sep; 14(9):611-3. PubMed ID: 16134100
[No Abstract] [Full Text] [Related]
19. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
[No Abstract] [Full Text] [Related]
20. Prescription drugs; revocation of final guideline patient package inserts and withdrawal of draft guideline patient package inserts--Food and Drug Administration. Notice.
Fed Regist; 1982 Sep; 47(173):39249-50. PubMed ID: 10258155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
